midazolam has been researched along with Acute Kidney Injury in 16 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Acute Kidney Injury: Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to investigate the effects of renal ischaemia/reperfusion (I/R)-induced acute kidney injury (AKI) on the distribution of midazolam (MDZ), a probe drug for cytochrome P450 3A (CYP3A) activity." | 7.91 | Effect of renal ischaemia/reperfusion-induced acute kidney injury on pharmacokinetics of midazolam in rats. ( Fumoto, S; Miyamoto, H; Nishida, K; Tokunaga, A, 2019) |
| "Acute strychnine poisoning is an uncommon form of intoxication, characterized by severe tonic clonic seizures and tetanus-like contractions while the patient is fully conscious." | 7.81 | [Strychnine poisoning: uncommon, but does still happen]. ( Arbouw, ME; Bles, CM; van Berlo-van de Laar, IR, 2015) |
| "Midazolam (1mg) was administered and the serum concentration of midazolam measured at 4 h." | 5.38 | Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. ( Holt, DW; Kirwan, CJ; Lee, T; MacPhee, IA; Philips, BJ, 2012) |
| "This study aimed to investigate the effects of renal ischaemia/reperfusion (I/R)-induced acute kidney injury (AKI) on the distribution of midazolam (MDZ), a probe drug for cytochrome P450 3A (CYP3A) activity." | 3.91 | Effect of renal ischaemia/reperfusion-induced acute kidney injury on pharmacokinetics of midazolam in rats. ( Fumoto, S; Miyamoto, H; Nishida, K; Tokunaga, A, 2019) |
| "Acute strychnine poisoning is an uncommon form of intoxication, characterized by severe tonic clonic seizures and tetanus-like contractions while the patient is fully conscious." | 3.81 | [Strychnine poisoning: uncommon, but does still happen]. ( Arbouw, ME; Bles, CM; van Berlo-van de Laar, IR, 2015) |
| " AKI unpredictably affects the pharmacokinetics and pharmacodynamics of drugs and dosing in patients with AKI is largely based on data from chronic kidney disease patients, but how appropriately is unknown." | 2.46 | Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity? ( Kirwan, C; MacPhee, I; Philips, B, 2010) |
| "Propofol was associated with lower AKI incidence using both urine output (45." | 1.42 | Renal Outcomes in Critically Ill Patients Receiving Propofol or Midazolam. ( Leite, TT; Libório, AB; Macedo, E; Martins, Ida S; Neves, FM, 2015) |
| "Midazolam (1mg) was administered and the serum concentration of midazolam measured at 4 h." | 1.38 | Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. ( Holt, DW; Kirwan, CJ; Lee, T; MacPhee, IA; Philips, BJ, 2012) |
| "Because of acute renal failure resulting from rhabdomyolysis hemodialysis was necessary three times." | 1.35 | ["Liquid ecstasy": gamma-butyrolactone withdrawal delirium with rhabdomyolysis and dialysis dependent renal failure]. ( Busch, HJ; Schwab, T; Supady, A, 2009) |
| "Twenty critically ill patients with acute renal failure on CVVH therapy were administered either lorazepam (n = 10) or midazolam (n = 10) by continuous infusion." | 1.33 | Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ( Danhof, M; de Jongh, J; Strack van Schijndel, RJ; Swart, EL; Thijs, LG; Zuideveld, KP, 2005) |
| " Consequently, its plasma elimination half-life after discontinuation was also greatly prolonged, but this shouldn't cause very prolonged sedative effects since this metabolite is much less active than the parent drug." | 1.28 | The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. ( Driessen, JJ; Guelen, PJ; Vree, TB, 1991) |
| " This situation demonstrates the difficulties of assessing the level of sedation as well as the dosage requirements in this type of patient." | 1.27 | Detection of overdosage of sedation in a patient with renal failure by the absence of lower oesophageal motility. ( Sinclair, ME; Suter, PM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Doi, M | 1 |
| Kajikawa, N | 2 |
| Aiba, T | 2 |
| Tokunaga, A | 1 |
| Miyamoto, H | 1 |
| Fumoto, S | 1 |
| Nishida, K | 1 |
| Zombori, L | 1 |
| Bacon, M | 1 |
| Wood, H | 1 |
| Chatterjee, F | 1 |
| Venkateswaran, R | 1 |
| Lampariello, S | 1 |
| Yoong, M | 1 |
| van Berlo-van de Laar, IR | 1 |
| Arbouw, ME | 1 |
| Bles, CM | 1 |
| Leite, TT | 1 |
| Macedo, E | 1 |
| Martins, Ida S | 1 |
| Neves, FM | 1 |
| Libório, AB | 1 |
| Kirwan, CJ | 2 |
| Lee, T | 2 |
| Holt, DW | 2 |
| Grounds, RM | 1 |
| MacPhee, IA | 2 |
| Philips, BJ | 2 |
| Supady, A | 1 |
| Schwab, T | 1 |
| Busch, HJ | 1 |
| Kirwan, C | 1 |
| MacPhee, I | 1 |
| Philips, B | 1 |
| Kusaba, J | 1 |
| Kawasaki, H | 1 |
| Kurosaki, Y | 1 |
| Strøm, T | 1 |
| Swart, EL | 1 |
| de Jongh, J | 1 |
| Zuideveld, KP | 1 |
| Danhof, M | 1 |
| Thijs, LG | 1 |
| Strack van Schijndel, RJ | 1 |
| Bouton, V | 1 |
| Bourget, P | 1 |
| Lesne-Hulin, A | 1 |
| Amstutz, P | 1 |
| Benayed, M | 1 |
| Benhamou, D | 1 |
| Dufieux, JL | 1 |
| Goursot, G | 1 |
| Grobuis, S | 1 |
| Haberer, JP | 1 |
| Jardin, F | 1 |
| Kirstetter, P | 1 |
| Marty, J | 1 |
| Mercatello, A | 1 |
| Page, B | 1 |
| Pourriat, JL | 1 |
| Vassal, T | 1 |
| Driessen, JJ | 1 |
| Vree, TB | 1 |
| Guelen, PJ | 1 |
| Williams, D | 1 |
| Dawson, P | 1 |
| Sinclair, ME | 1 |
| Suter, PM | 1 |
1 review available for midazolam and Acute Kidney Injury
| Article | Year |
|---|---|
Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?
Topics: Acute Kidney Injury; Animals; Critical Illness; Cytochrome P-450 CYP3A; Humans; Liver; Midazolam | 2010 |
2 trials available for midazolam and Acute Kidney Injury
| Article | Year |
|---|---|
Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Area Under Curve; Critical Illness; Cytochrome P-450 C | 2009 |
Influence of acute renal failure on FPIA rapid serum assay of midazolam and its main metabolite.
Topics: Acute Kidney Injury; Adult; Aged; Anesthetics, Intravenous; Chromatography, High Pressure Liquid; Fe | 1997 |
13 other studies available for midazolam and Acute Kidney Injury
| Article | Year |
|---|---|
Effects of dexamethasone to reverse decreased hepatic midazolam metabolism in rats with acute renal failure.
Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Cytochrome P-450 CYP3A; Dexamethasone; Metab | 2020 |
Effect of renal ischaemia/reperfusion-induced acute kidney injury on pharmacokinetics of midazolam in rats.
Topics: Acute Kidney Injury; Animals; Cytochrome P-450 CYP3A; Disease Models, Animal; Male; Midazolam; Prote | 2019 |
Severe cortical damage associated with COVID-19 case report.
Topics: Acute Kidney Injury; Adolescent; Airway Extubation; Anticonvulsants; Blood Coagulation Disorders; Bo | 2021 |
[Strychnine poisoning: uncommon, but does still happen].
Topics: Acute Kidney Injury; Emergency Treatment; Epilepsy, Tonic-Clonic; Fever; Humans; Male; Midazolam; Mi | 2015 |
Renal Outcomes in Critically Ill Patients Receiving Propofol or Midazolam.
Topics: Acute Kidney Injury; Aged; Anesthetics, Intravenous; Cohort Studies; Critical Illness; Female; Human | 2015 |
["Liquid ecstasy": gamma-butyrolactone withdrawal delirium with rhabdomyolysis and dialysis dependent renal failure].
Topics: 4-Butyrolactone; Acute Kidney Injury; Adrenergic alpha-Agonists; Benzodiazepines; Clonidine; GABA Mo | 2009 |
Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients.
Topics: Acute Kidney Injury; Anesthetics, Intravenous; Critical Illness; Cytochrome P-450 CYP3A; Genotype; H | 2012 |
Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure.
Topics: Acute Kidney Injury; Animals; Cytochrome P-450 CYP3A; Glycerol; Male; Microsomes, Liver; Midazolam; | 2012 |
Sedation in the ICU.
Topics: Academic Dissertations as Topic; Acute Kidney Injury; Aged; Anxiety; Critical Care; Deep Sedation; D | 2012 |
Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Adult; Aged; Conscious Sedation; Drug Administration Schedule; Drug Evaluation; | 2005 |
The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients.
Topics: Acute Kidney Injury; Critical Illness; Female; Glucuronates; Humans; Infusions, Intravenous; Male; M | 1991 |
An unusual result with flumazenil.
Topics: Acute Kidney Injury; Critical Care; Female; Flumazenil; Humans; Midazolam; Middle Aged; Nervous Syst | 1989 |
Detection of overdosage of sedation in a patient with renal failure by the absence of lower oesophageal motility.
Topics: Acute Kidney Injury; Adult; Esophagus; Hemofiltration; Humans; Hypnotics and Sedatives; Male; Midazo | 1988 |